This study is looking into whether N-acetyl cysteine (NAC) eye drops can help people with Fuchs' Endothelial Corneal Dystrophy (FECD), a common eye condition that affects the cornea. Currently, the main treatment for FECD is corneal transplant surgery, and there are no medical treatments to slow its progress. Researchers believe that NAC eye drops might reduce stress on the cells in your eye and protect them. You could be eligible if you are at least 21 years old, have advanced FECD and cataracts, and are scheduled for a specific type of corneal transplant surgery (DMEK) along with cataract surgery. The study will measure the level of a substance called H2O2 in your eye fluid during your surgery to see if the NAC eye drops are working.

Study design

This is a single-center, randomized, double-blind, placebo-controlled study involving 45 participants. Participants will receive either N-acetyl cysteine (NAC) 10% solution, N-acetyl cysteine (NAC) 20% solution, or Visine Dry Eye Relief eye drops.

What's involved

The primary measurement for the study will occur during DMEK surgery, which happens 28 to 42 days after you join the study.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint is measured at DMEK surgery, which occurs 28 to 42 days after enrollment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.